Title: Glucagon-like peptide-1 receptor activation and mental health: a drug-target

Mendelian randomization study

Short title: GLP-1R and mental health

Authors:

Guoyi Yang, PhD[a,b*], Stephen Burgess, PhD[c,d], C Mary Schooling, PhD[a,e]

[a] School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong

Kong, Hong Kong, China

[b] Department of Medicine, Perelman School of Medicine, University of Pennsylvania,

Philadelphia, USA

[c] MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

[d] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public

Health and Primary Care, University of Cambridge, Cambridge, UK

[e] Graduate School of Public Health and Health Policy, City University of New York,

New York, USA

[*]**Corresponding author: Guoyi Yang, PhD**

Postal address: 1/F, Patrick Manson Building, 7 Sassoon Road, Pokfulam, Hong Kong

Email address: yanggy@connect.hku.hk

Telephone: +852 98147624

ORCID: 0000-0002-4387-386X

Word count: 2984

The number of tables: 0

The number of figures: 4

Abstract

Concerns have been raised about the psychiatric safety of glucagon-like peptide-1

receptor (GLP-1R) agonists, but trial evidence suggests that they ameliorate

depressive symptoms. We aimed to assess the associations of GLP-1R activation with

mental health well-being and the risk of mental health disorders and substance use

disorders. We performed drug-target Mendelian randomization and colocalization

analyses using the largest relevant publicly available genome-wide association studies

in European ancestry individuals. After correcting for multiple comparisons,

genetically predicted lower body mass index (BMI) via GLP-1R activation was

associated with a better well-being spectrum (0.06 standard deviation [95%

confidence interval 0.03-0.08]) and lower risk of depression (odds ratio 0.83 [0.74-

0.94]) and bipolar disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m^2 decrease in BMI.

There was also suggestive evidence that genetically predicted lower BMI via GLP-1R

activation was associated with lower risk of post-partum depression, attention deficit

hyperactivity disorder, and substance use disorders, and that genetically predicted

lower glycated hemoglobin (HbA1c) via GLP-1R activation was associated with

higher risk of anorexia nervosa but lower risk of Tourette syndrome. These

associations were stronger than the associations for genetically predicted lower BMI

and lower HbA1c based on genome-wide variants. The posterior probabilities of a

shared causal variant affecting both BMI and the outcome at the *GLP1R* gene were

59.3% for the well-being spectrum, 3.8% for depression, and 45.9% for bipolar

disorder. GLP-1R activation was associated with better mental health well-being and

lower risk of depression and bipolar disorder beyond that expected from the reduction

in BMI and HbA1c.

(Word count: 250)

Keywords: bipolar disorder, depression, glucagon-like peptide-1 receptor, Mendelian

randomization, mental health

Introduction

Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce body weight and blood glucose.[1] Randomized controlled trials (RCTs) have shown cardiovascular and mortality benefits of GLP-1R agonists.[2,3] GLP-1R agonists act on the hindbrain, the hypothalamus, and vagal afferents to suppress food intake and reduce body weight.[4-6] Anti-obesity drugs affecting central nervous systems could have psychiatric effects. For example, the combination of phentermine and topiramate increases depression and anxiety.[7] Rimonabant was withdrawn from the market due to serious psychiatric adverse effects.[8] In contrast, the combination of naltrexone and bupropion improves depression,[9] smoking cessation,[10,11] and methamphetamine use disorder.[12]

Following reports of suicidal ideation and self-injury in people using GLP-1R agonists,[13] the European Medicines Agency and the US Food and Drug Administration have been monitoring the psychiatric safety of GLP-1R agonists. To date, the available evidence does not suggest a causal association of GLP-1R agonist use with suicidal thoughts and actions.[14,15] RCTs have suggested that GLP-1R agonists moderately reduce depressive symptoms in people who are overweight or obese[16] and in people with type 2 diabetes.[17] Animal studies[18,19] and observational studies[20,21] suggest potential benefits of GLP-1R agonists in alcohol use disorder, but evidence from RCTs is lacking.[22] Early-stage trials are on-going to investigate the efficacy of GLP-1R agonists in individuals with mental illnesses[23] and substance use

disorders.[24] A better understanding of the association of GLP-1R activation, the

intended target of GLP-1R agonists, with mental health has implications for informing

their psychiatric safety and potential repurposing opportunities.

Mendelian randomization (MR), an instrumental variable analysis with genetic

instrument, is less confounded than conventional observational studies.[25] Previous

MR studies suggested no association of GLP-1R activation with suicide risk,[26,27]

consistent with an RCT.[16] We used MR to assess the associations of GLP-1R

activation with mental health outcomes including the well-being spectrum, mental

health disorders, and substance use disorders. We further investigated whether any

associations were explained by lowering body mass index (BMI) or lowering glycated

hemoglobin (HbA1c).

Subjects and methods

Ethical approval of studies and informed consent

All the analyses were conducted using publicly available summary statistics, which

does not require ethical approval.

Study design

MR relies on the instrumental variable assumptions of relevance (the genetic

instruments should be related to the exposure), independence (no common cause of

the genetic instruments and the outcome exists), and exclusion restriction (the genetic

instruments should be independent of the outcome given the exposure).[28] This MR

study took advantage of the largest relevant publicly available genome-wide

association studies (GWASs) (eTable 1). First, we assessed the associations of GLP-

1R activation predicted by *GLP1R* variants with mental health outcomes including the

well-being spectrum, mental health disorders, and substance use disorders. We

compared these associations with the associations for lower BMI and lower HbA1c

predicted by genome-wide variants. Second, we performed colocalization analyses to

examine whether any associations found for GLP-1R activation were driven by a

shared causal variant affecting both BMI or HbA1c and the outcome at the *GLP1R*

gene.[29] Where possible, we conducted sex-specific analyses, because women are more

likely to have depression than men,[30] but boys are more likely to develop

neurodevelopmental disorders than girls.[31]

Genetic instruments

We selected genetic instruments for GLP-1R activation based on their associations

with BMI ($N = 806{,}834$) from a meta-analysis of the UK Biobank and GIANT[32] and

with HbA1c ($N = 344{,}182$) from a GWAS of the UK Biobank.[33] We considered these

two sets of instruments separately, because they might represent distinct

mechanisms.[34] To mimic BMI-related mechanisms, we extracted variants in or near

(+- 1Mb) the *GLP1R* gene that were uncorrelated ($r^2 < 0.001$) and genome-wide

significantly (*p* value $<5 \times 10^{-8}$) associated with BMI. To mimic HbA1c-related

mechanisms, we used the same approach based on their associations with HbA1c. We

also extracted genetic instruments for BMI and HbA1c from across the genome

(genome-wide variants) that were uncorrelated ($r^2 < 0.001$) and genome-wide

significantly (*p* value $<5 \times 10^{-8}$) associated with BMI and HbA1c, respectively.

We used coronary artery disease (CAD) and all-cause mortality as positive control

outcomes, because RCTs have shown that GLP-1R agonists reduce cardiovascular

events and death.[2,3] We obtained genetic associations with CAD (181,522

cases/984,168 controls) from a meta-analysis of the CARDIoGRAMplusC4D

consortium and the UK Biobank.[35] We obtained genetic associations with parental

mortality (609,139 cases/403,101 controls) from a meta-analysis of the UK Biobank

and LifeGen as a measure of all-cause mortality,[36] because it has more power than

participant's mortality.

Genetic associations with mental health outcomes

We obtained sex-combined and sex-specific genetic associations with mental health

outcomes from the largest relevant publicly available GWASs.[33,37-51] Primary

outcomes included the well-being spectrum, mental health disorders (depression,

bipolar disorder, post-traumatic stress disorder (PTSD), schizophrenia, anorexia

nervosa, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder,

and Tourette's syndrome), and substance use disorders. Secondary outcomes included

four dimensions of mental health well-being (life satisfaction, positive affect,

neuroticism, and depressive symptoms) and subtypes of mental health disorders

(postpartum depression and bipolar disorder I and II) and substance use disorders

(cannabis use disorder and alcohol dependence). Secondary outcomes also included

the Alcohol Use Disorders Identification Test (AUDIT) total score, score for alcohol

consumption, and score for alcohol problems. Genetic associations with binary

outcomes obtained using linear regression were transformed into odds ratio (OR)

using an established approximation.[52]

MR analysis

We used the F-statistic to assess instrument strength, approximated by the square of

SNP-exposure association divided by the square of its standard error.[53] An F-statistic

larger than 10 suggests weak instrument bias is unlikely. We aligned SNPs on the

same allele for exposure and outcome, and used proxy SNPs ($r^2 > 0.8$), where possible,

when SNPs were not available in the outcome GWAS. We calculated Wald estimates

by dividing genetic association with outcome by genetic association with exposure.

We obtained MR estimates by meta-analyzing Wald estimates using inverse variance

weighting (IVW) with fixed effects for three SNPs or fewer and random effects for

four SNPs or more.[54] To assess the robustness of IVW estimates, we conducted

sensitivity analyses using the weighted median[55] and MR Egger.[56] The MR Egger

intercept assesses directional pleiotropy.[56] We used a Bonferroni corrected

significance level of $\alpha=0.05/10=0.005$ given ten primary outcomes. We considered

nominally significant associations (*p* value <0.05) that did not reach Bonferroni

corrected significance as suggestive evidence. We tested differences by sex using a

two-sided z-test.[57]

Colocalization

We performed colocalization analyses in a Bayesian framework to assess whether any

associations found for GLP-1R activation were driven by a shared causal variant

affecting both BMI or HbA1c and the outcome or were confounded by linkage

disequilibrium.[29] We assessed the posterior probability of several hypotheses,

including H_0 (no association with either trait), H_1, (association with BMI or HbA1c

only); H_2, (association with the outcome only); H_3, (associations of two independent

variants and one for each trait); H_4 (associations of one shared variant with both

traits).[29] A posterior probability of H_4 larger than 0.80 suggests colocalization.[29] The

power to detect colocalization is low when the variants are not strongly associated

with the outcome,[58] so we also calculated the posterior probability of H_4 conditional

on the presence of a variant associated with the outcome ($H_2 + H_3 + H_4$). We included

variants (minor allele frequency >0.1%) in or near (+- 1Mb) the *GLP1R* gene. We set

the prior probabilities as recommended, that is 10^{-4} for a variant associated with BMI

or HbA1c, 10^{-4} for a variant associated with the outcome, and 10^{-5} for a variant

associated with both traits.[29] All statistical analyses were conducted using R version

4.2.1 and the packages "ieugwasr", "TwoSampleMR", "MendelianRandomization",

"metafor", and "coloc".

Results

Genetic instruments

To genetically predict lower BMI via GLP-1R activation, we obtained two *GLP1R*

SNPs (rs17757975 and rs4714290) based on their associations with BMI (eTable 2).

To genetically predict lower HbA1c via GLP-1R activation, we obtained one *GLP1R*

SNP (rs10305518) based on its association with HbA1c (eTable 2). The *GLP1R* SNPs

for BMI were not associated with HbA1c and vice versa (eTable 3), which

substantiated that they represent distinct mechanisms.[34] We also extracted 516

(overall), 303 (women), and 256 (men) SNPs for BMI and 318 (overall), 200

(women), 174 (men) SNPs for HbA1c from across the genome (eTable 4). The F-

statistics were all >10 (eTables 2 and 4).

In positive control analyses, genetically predicted lower BMI and lower HbA1c via

GLP-1R activation were associated with lower CAD risk and all-cause mortality,

despite wide confidence intervals (CIs) (eFigure 1). The point estimates suggested

similar or stronger associations for genetically predicted GLP-1R activation than for

genetically predicted lower BMI and lower HbA1c based on genome-wide variants

(eFigure 1 and eTable 5).

Associations of GLP-1R activation with mental health well-being

Genetically predicted lower BMI via GLP-1R activation was associated with a better

well-being spectrum, including life satisfaction, positive affect, neuroticism, and

depressive symptoms (Figure 1). The associations with depressive symptoms were

similar in women and men (eFigure 2). These associations were stronger than the

associations for genetically predicted lower BMI using genome-wide variants (Figure

1 and eTables 6-7). However, genetically predicted lower HbA1c via GLP-1R

activation had little association with mental health well-being (Figure 1).

Associations of GLP-1R activation with the risk of mental health disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower

risk of depression, postpartum depression, bipolar disorder, bipolar disorder I and II,

and ADHD (Figure 2). The association with depression was possibly stronger in

women (OR (95% CI) 0.75 (0.52 to 1.08)) than men (0.98 (0.65 to 1.47)), although

the *p* value for sex difference was 0.35 (eFigure 3). These associations were stronger

than the associations for genetically predicted lower BMI using genome-wide variants

(Figure 2 and eTable 8). Genetically predicted lower HbA1c via GLP-1R activation

was associated with higher risk of anorexia nervosa but lower risk of Tourette

syndrome, with stronger associations than the associations for genetically predicted

lower HbA1c using genome-wide variants (Figure 2 and eTable 8).

Associations of GLP-1R activation with the risk of substance use disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower

risk of substance use disorders and lower AUDIT score for alcohol problems, with

stronger associations than the associations for genetically predicted lower BMI using

genome-wide variants (Figure 3 and eTable 9). However, genetically predicted lower

HbA1c via GLP-1R activation had little association with the risk of substance use

disorders (Figure 3).

Colocalization

After correcting for multiple comparisons, genetically predicted lower BMI via GLP-

1R activation remained significantly associated with the well-being spectrum, life

satisfaction, positive affect, neuroticism, depressive symptoms, depression, bipolar

disorder, and bipolar disorder I (p values <0.005). Colocalization analyses were

performed for BMI and each significant outcome in or near (+- 1Mb) the *GLP1R*

gene. The posterior probabilities of a shared causal variant associated with both traits

were <80% for all the significant outcomes, but they were >80% when conditioning

on the presence of a variant associated with the outcome except for depression (Figure

4). The posterior probabilities of two independent variants associated with each trait

were <15% for all the significant outcomes (eTable 10). Conditioning on the presence

of a shared causal variant associated with both traits, rs4714290, rs847784 (a proxy

for rs4714290, $r^2 = 0.89$), or rs17757975 had the largest probability of being the

shared variant.

Discussion

Consistent with RCTs,[16,17] this MR study suggests that GLP-1R activation is

associated with lower risk of depression. We build on the evidence base by showing

that GLP-1R activation is associated with a better well-being spectrum and lower risk

of bipolar disorder. We also provide suggestive evidence that GLP-1R activation is

associated with lower risk of postpartum depression, ADHD, Tourette syndrome, and

substance use disorders but higher risk of anorexia nervosa. These associations were

stronger than those expected from the reduction in BMI and HbA1c.

Our investigations suggest that GLP-1R activation is associated with a better well-

being spectrum and lower risk of depression and bipolar disorder. Consistently, RCTs

have shown that GLP-1R agonists moderately reduce depression symptoms in

overweight people[16] and in people with type 2 diabetes.[17] A small open-label trial

showed that liraglutide improved cognitive function[59] and brain volumes[60] in people

with depression or bipolar disorder. GLP-1 has neuroprotective effects including

enhanced neurogenesis, improved barrier function, reduced neuroinflammation, and

decreased oxidative stress.[61] These effects might contribute to the psychiatric benefits

of GLP-1R activation and are consistent with RCTs showing that GLP-1R agonists

improve neurodegenerative diseases, such as Parkinson's disease.[62,63]

Interestingly, the associations of GLP-1R activation with mental health well-being,

depression, and bipolar disorder were evident when instrumenting on BMI but not on

HbA1c, suggesting the relevance of BMI-related mechanisms. A recent study showed

that GLP-1R agonists target the hindbrain dorsal vagal complex to decrease food

intake and body weight.[4] Actions on the hypothalamus and vagal afferents also

contribute to the weight loss on GLP-1R agonists.[5,6] GLP neurons in the dorsal vagal

complex moderate stress responses and stimulate hypothalamic-pituitary-adrenal

(HPA) axis activity, which has been implicated in the pathology of depression[64] and

bipolar disorder.[65] Notably, the HPA axis is also related to cognitive function,[64,65]

consistent with an RCT showing that dulaglutide reduces cognitive impairment in

people with type 2 diabetes.[66] Additional studies are warranted to elucidate the

mechanisms underlying potential benefits of GLP-1R agonists for mental health.

We found that GLP-1R activation was possibly associated with lower risk of

depression more in women than men and was associated with lower risk of

postpartum depression. Women are about twice as likely as men to have depression

during their lifetime with the difference starting at puberty.[30] A meta-analysis of RCTs

showed that GLP-1R agonists decreased testosterone and increased sex hormone-

binding globulin in women with polycystic ovary syndrome,[67] but their effects on

estrogen are less clear. Sex hormones might contribute to GLP-1R activation

improving depression in women, given their potential roles in modulating

serotonergic neurotransmission, cortisol, and oxytocin.[68]

GLP-1R activation was not associated with higher risk of neurodevelopmental

disorders including ADHD, autism spectrum disorder, and Tourette syndrome. RCTs

have showed the short-term (no more than 26 weeks) safety of GLP-1R agonists in

children and adolescents.[69] We add to the evidence by suggesting that lifelong GLP-

1R activation is not associated with adverse effects on neurodevelopmental disorders,

which usually take a longer period of time to develop and have been less considered

in RCTs. However, GLP-1R activation was possibly associated with higher risk of

anorexia nervosa when instrumenting on HbA1c. GLP-1R activation increases insulin

secretion and sensitivity and lowers glucose.[70] A previous MR study suggested an

inverse association of fasting insulin with the risk of anorexia nervosa,[71] indicating a

role of insulin sensitivity.

We provide suggestive evidence that GLP-1R activation is associated with lower risk

of substance use disorders and lower AUDIT score for alcohol problems. This finding

is consistent with animal studies[18,19] and observational studies[20,21] showing potential

benefits of GLP-1R agonists for alcohol use disorder. However, the only RCT

including people with alcohol use disorder showed that 26 weeks of treatment with

exenatide did not significantly reduce heavy drinking days, although exenatide

attenuated fMRI alcohol cue reactivity in brain areas for drug reward and addiction.[22]

More evidence from RCTs is needed to determine the repurposing opportunities of

GLP-1R agonists for treating substance use disorders.

The associations of GLP-1R activation with mental health outcomes were stronger

than those expected from lowering BMI and HbA1c. Correspondingly, RCTs have

showed that semaglutide reduces cardiovascular events and mortality more than

expected from the reduction in body weight,[16] and that GLP-1R agonists outperform

other anti-diabetes drugs.[72] Apart from reducing body weight and glucose, GLP-1R

agonists also decrease blood pressure, low-density lipoprotein cholesterol, and

inflammation and enhance kidney function.[2,3] We extend the evidence by suggesting

that GLP-1R activation is associated with better mental health beyond that expected

from the reduction in BMI and HbA1c, which may also contribute to the

cardiovascular and mortality benefits of GLP-1R agonists.[73] A parsimonious model

explaining the multifaceted effects of GLP-1R agonists would be helpful. For

example, GLP-1R agonists activating AMP-activated protein kinase (AMPK)[74] can

explain several aspects of their benefits, given the central role of AMPK in

metabolism across tissues including the brain.[75]

This is the first drug-target MR study comprehensively exploring the associations of

GLP-1R activation with mental health outcomes. The finding that GLP-1R activation

is associated with better mental health well-being and lower risk of bipolar disorder is

novel. Our investigation also has implications for the use of GLP-1R agonists in

people with mental health disorders, who usually have higher risk of obesity and type

2 diabetes but are undertreated. This study has several limitations. First, MR relies on

three rigorous assumptions, that is genetic instruments should be related to the

exposure, share no common cause with the outcome, and be independent of the

outcome given the exposure.[28] The F-statistics were >10, suggesting minimal weak

instrument bias. We validated the genetic instruments using CAD and all-cause

mortality as positive control outcomes. Second, we selected genetic instruments for

GLP-1R activation based on their associations with BMI and HbA1c, but additional

underlying factors may explain their psychiatric effects. Instrumenting on BMI and

HbA1c could have masked some effects of GLP-1R activation. Third, the power to

detect colocalization was insufficient. However, the posterior probabilities of two

independent variants associated with each trait were <15% for all the significant

outcomes, suggesting that the associations found were unlikely driven by confounding

due to linkage disequilibrium. Fourth, MR can be open to selection bias from

selecting on genetic makeup and mental health disorders. Nevertheless, such selection

should bias towards a harmful effect of GLP-1R activation, which does not explain its

associations with lower risk of depression and bipolar disorder. Fifth, mental health

disorders sometimes originate during childhood or adolescence, but GLP-1R agonists

are primarily used in adults. MR assesses lifelong effects of GLP-1R activation on

mental health, which cannot directly inform the quantitative short-term effects of

GLP-1R agonists. RCTs are warranted to determine the clinical relevance of these

findings in the future.

Conclusions

This drug-target MR study provides genetic evidence that GLP-1R activation is

associated with better mental health well-being and lower risk of depression and

bipolar disorder beyond that expected from the reduction in BMI and HbA1c.

Acknowledgements

The authors acknowledge Pulit SL, et al., the Neale lab, the CARDIoGRAMplusC4D

Consortium, Timmers PR, et al., Baselmans BML, et al., and the Psychiatric

Genomics Consortium for their publicly available summary data.

Funding

SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom

Research and Innovation Medical Research Council (MC_UU_00002/7). The funders

had no role in the study design, analyses, or interpretation of results.

Conflict of interest

372 The authors declared no conflict of interest.

Data availability

Summary statistics analyzed are available in the website

https://doi.org/10.5281/zenodo.1251813 for BMI, http://www.nealelab.is/uk-biobank/

for HbA1c, https://www.cardiogramplusc4d.org/data-downloads/ for CAD,

https://www.ebi.ac.uk/gwas/publications/30642433 for parental mortality,

https://www.ebi.ac.uk/gwas/publications/30643256 for mental health well-being,

https://pgc.unc.edu/for-researchers/download-results/ for mental health disorders and

substance use disorders.

Contribution statement

384 GY and CMS designed the study. GY undertook analyses with feedback from SB and

385 CMS. GY drafted the manuscript with critical feedback and revisions from SB and

386 CMS. All authors read and approved the final version of the manuscript. GY had full

387 access to all the data in the study and takes responsibility for the integrity of the data

388 and the accuracy of the data analysis.

Artificial intelligence (AI)-assisted technologies

391 The authors declared that AI-assisted technologies were not used in this study.

References

1   Andersen, A., Lund, A., Knop, F. K. & Vilsbøll, T. Glucagon-like peptide 1 in health and disease. *Nature reviews. Endocrinology* **14**, 390-403, doi:10.1038/s41574-018-0016-2 (2018).

2   Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S. *et al.* Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *The New England journal of medicine* **389**, 2221-2232, doi:10.1056/NEJMoa2307563 (2023).

3   Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S. *et al.* Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *The lancet. Diabetes & endocrinology* **9**, 653-662, doi:10.1016/s2213-8587(21)00203-5 (2021).

4   Huang, K. P., Acosta, A. A., Ghidewon, M. Y., McKnight, A. D., Almeida, M. S., Nyema, N. T. *et al.* Dissociable hindbrain GLP1R circuits for satiety and aversion. *Nature*, doi:10.1038/s41586-024-07685-6 (2024).

5   Burmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J. *et al.* The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice. *Diabetes* **66**, 372-384, doi:10.2337/db16-1102 (2017).

6   Krieger, J. P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W. & Lee, S.

J. Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food

Intake and Glycemia. *Diabetes* **65**, 34-43, doi:10.2337/db15-0973 (2016).

7   Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B.,

Schwiers, M. L. *et al.* Effects of low-dose, controlled-release, phentermine

plus topiramate combination on weight and associated comorbidities in

overweight and obese adults (CONQUER): a randomised, placebo-controlled,

phase 3 trial. *Lancet (London, England)* **377**, 1341-1352, doi:10.1016/s0140-

6736(11)60205-5 (2011).

8   Topol, E. J., Bousser, M. G., Fox, K. A., Creager, M. A., Despres, J. P., Easton,

J. D. *et al.* Rimonabant for prevention of cardiovascular events

(CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet*

(London, England) **376**, 517-523, doi:10.1016/s0140-6736(10)60935-x

(2010).

9   Pi-Sunyer, X., Apovian, C. M., McElroy, S. L., Dunayevich, E., Acevedo, L.

M. & Greenway, F. L. Psychiatric adverse events and effects on mood with

prolonged-release naltrexone/bupropion combination therapy: a pooled

analysis. *International journal of obesity (2005)* **43**, 2085-2094,

doi:10.1038/s41366-018-0302-z (2019).

10   Hurt, R. D., Sachs, D. P., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L.

C. *et al.* A comparison of sustained-release bupropion and placebo for

439   smoking cessation. *The New England journal of medicine* **337**, 1195-1202,

440   doi:10.1056/nejm199710233371703 (1997).

441 11 Mooney, M. E., Schmitz, J. M., Allen, S., Grabowski, J., Pentel, P., Oliver, A.

442   *et al.* Bupropion and naltrexone for smoking cessation: A double-blind

443   randomized placebo-controlled clinical trial. *Clinical pharmacology and*

444   *therapeutics* **100**, 344-352, doi:10.1002/cpt.402 (2016).

445 12 Trivedi, M. H., Walker, R., Ling, W., Dela Cruz, A., Sharma, G., Carmody, T.

446   *et al.* Bupropion and Naltrexone in Methamphetamine Use Disorder. *The New*

447   *England journal of medicine* **384**, 140-153, doi:10.1056/NEJMoa2020214

448   (2021).

449 13 *European Medicines Agency. EMA statement on ongoing review of GLP-1*

450   *receptor agonists*, <https://www.ema.europa.eu/en/news/ema-statement-

451   ongoing-review-glp-1-receptor-agonists> (2023).

452 14 *European Medicines Agency. Meeting highlights from the Pharmacovigilance*

453   *Risk Assessment Committee (PRAC) 8-11 April 2024.*,

454   <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-

455   risk-assessment-committee-prac-8-11-april-2024> (2024).

456 15 *US Food and Drug Administration. Update on FDA's ongoing evaluation of*

457   *reports of suicidal thoughts or actions in patients taking a certain type of*

458   *medicines approved for type 2 diabetes and obesity.*,

459   <https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-

evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type>

(2024).

16 Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B.,

Kushner, R. F. *et al.* Psychiatric Safety of Semaglutide for Weight

Management in People Without Known Major Psychopathology: Post Hoc

Analysis of the STEP 1, 2, 3, and 5 Trials. *JAMA internal medicine*,

doi:10.1001/jamainternmed.2024.4346 (2024).

17 Chen, X., Zhao, P., Wang, W., Guo, L. & Pan, Q. The Antidepressant Effects

of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. *The*

American journal of geriatric psychiatry : official journal of the American

Association for Geriatric Psychiatry **32**, 117-127,

doi:10.1016/j.jagp.2023.08.010 (2024).

18 Suchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C.,

Momenan, R. *et al.* The glucagon-like peptide-1 receptor as a potential

treatment target in alcohol use disorder: evidence from human genetic

association studies and a mouse model of alcohol dependence. *Translational*

psychiatry **5**, e583, doi:10.1038/tp.2015.68 (2015).

19 Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid

Sköldheden, S. *et al.* Semaglutide reduces alcohol intake and relapse-like

drinking in male and female rats. *EBioMedicine* **93**, 104642,

doi:10.1016/j.ebiom.2023.104642 (2023).

20   Wium-Andersen, I. K., Wium-Andersen, M. K., Fink-Jensen, A., Rungby, J.,

Jørgensen, M. B. & Osler, M. Use of GLP-1 receptor agonists and subsequent

risk of alcohol-related events. A nationwide register-based cohort and self-

controlled case series study. *Basic & clinical pharmacology & toxicology* **131**,

372-379, doi:10.1111/bcpt.13776 (2022).

21   Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C. & Xu, R.

Associations of semaglutide with incidence and recurrence of alcohol use

disorder in real-world population. *Nature communications* **15**, 4548,

doi:10.1038/s41467-024-48780-6 (2024).

22   Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A., Zeeman,

V. A. *et al.* Exenatide once weekly for alcohol use disorder investigated in a

randomized, placebo-controlled clinical trial. *JCI insight* **7**,

doi:10.1172/jci.insight.159863 (2022).

23   Ganeshalingam, A. A., Uhrenholt, N. G., Arnfred, S., Gæde, P. H., Bilenberg,

N. & Frystyk, J. Home-based Intervention with Semaglutide Treatment of

Neuroleptic-Related Prediabetes (HISTORI): protocol describing a

prospective, randomised, placebo controlled and double-blinded multicentre

trial. *BMJ open* **14**, e077173, doi:10.1136/bmjopen-2023-077173 (2024).

24   Köhne, S., Hillemacher, T., Glahn, A. & Bach, P. Emerging drugs in phase II

and III clinical development for the treatment of alcohol use disorder. *Expert*

opinion on emerging drugs **29**, 219-232, doi:10.1080/14728214.2024.2342951

(2024).

25   Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G.

Mendelian randomization: using genes as instruments for making causal

inferences in epidemiology. *Statistics in medicine* **27**, 1133-1163,

doi:10.1002/sim.3034 (2008).

26   Zhao, S. S., Burgess, S. & Gill, D. Glucagon-Like Peptide-1 Receptor

Agonism and Suicide Risk: Evidence From Mendelian Randomization.

Journal of the American Heart Association **13**, e035948,

doi:10.1161/jaha.124.035948 (2024).

27   Nguyen, A., Smith, E., Hashemy, H., Agarwal, S. M., Hahn, M. K., Paterson,

A. D. *et al.* Glucagon-like-peptide 1 receptor agonism and attempted suicide:

A Mendelian randomisation study to assess a potential causal association.

Clinical obesity **14**, e12676, doi:10.1111/cob.12676 (2024).

28   Didelez, V. & Sheehan, N. Mendelian randomization as an instrumental

variable approach to causal inference. *Statistical methods in medical research*

16, 309-330, doi:10.1177/0962280206077743 (2007).

29   Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D.,

Wallace, C. *et al.* Bayesian test for colocalisation between pairs of genetic

association studies using summary statistics. *PLoS genetics* **10**, e1004383,

doi:10.1371/journal.pgen.1004383 (2014).

30   Kuehner, C. Why is depression more common among women than among

men? *The lancet. Psychiatry* **4**, 146-158, doi:10.1016/s2215-0366(16)30263-2

(2017).

31   Bölte, S., Neufeld, J., Marschik, P. B., Williams, Z. J., Gallagher, L. & Lai, M.

C. Sex and gender in neurodevelopmental conditions. *Nature reviews.*

Neurology **19**, 136-159, doi:10.1038/s41582-023-00774-6 (2023).

32   Locke, A. E., Kahali, B., Berndt, S. I., Justice, A. E., Pers, T. H., Day, F. R. *et*

al. Genetic studies of body mass index yield new insights for obesity biology.

Nature **518**, 197-206, doi:10.1038/nature14177 (2015).

33   *UK Biobank (Neale lab). http://www.nealelab.is/uk-biobank/.*

34   Patel, A., Gill, D., Shungin, D., Mantzoros, C. S., Knudsen, L. B., Bowden, J.

et al. Robust use of phenotypic heterogeneity at drug target genes for

mechanistic insights: Application of cis-multivariable Mendelian

randomization to GLP1R gene region. *Genetic epidemiology* **48**, 151-163,

doi:10.1002/gepi.22551 (2024).

35   Aragam, K. G., Jiang, T., Goel, A., Kanoni, S., Wolford, B. N., Atri, D. S. *et*

al. Discovery and systematic characterization of risk variants and genes for

coronary artery disease in over a million participants. *Nature genetics* **54**,

1803-1815, doi:10.1038/s41588-022-01233-6 (2022).

36   Timmers, P. R., Mounier, N., Lall, K., Fischer, K., Ning, Z., Feng, X. *et al.*

Genomics of 1 million parent lifespans implicates novel pathways and

common diseases and distinguishes survival chances. *eLife* **8**,

544  doi:10.7554/eLife.39856 (2019).

545 37 Baselmans, B. M. L., Jansen, R., Ip, H. F., van Dongen, J., Abdellaoui, A., van

546  de Weijer, M. P. *et al.* Multivariate genome-wide analyses of the well-being

547  spectrum. *Nature genetics* **51**, 445-451, doi:10.1038/s41588-018-0320-8

548  (2019).

549 38 Howard, D. M., Adams, M. J., Clarke, T. K., Hafferty, J. D., Gibson, J.,

550  Shirali, M. *et al.* Genome-wide meta-analysis of depression identifies 102

551  independent variants and highlights the importance of the prefrontal brain

552  regions. *Nature neuroscience* **22**, 343-352, doi:10.1038/s41593-018-0326-7

553  (2019).

554 39 Guintivano, J., Byrne, E. M., Kiewa, J., Yao, S., Bauer, A. E., Aberg, K. A. *et*

555  *al.* Meta-Analyses of Genome-Wide Association Studies for Postpartum

556  Depression. *The American journal of psychiatry* **180**, 884-895,

557  doi:10.1176/appi.ajp.20230053 (2023).

558 40 Mullins, N., Forstner, A. J., O'Connell, K. S., Coombes, B., Coleman, J. R. I.,

559  Qiao, Z. *et al.* Genome-wide association study of more than 40,000 bipolar

560  disorder cases provides new insights into the underlying biology. *Nature*

561  *genetics* **53**, 817-829, doi:10.1038/s41588-021-00857-4 (2021).

562 41 Nievergelt, C. M., Maihofer, A. X., Klengel, T., Atkinson, E. G., Chen, C. Y.,

563  Choi, K. W. *et al.* International meta-analysis of PTSD genome-wide

564  association studies identifies sex- and ancestry-specific genetic risk loci.

565  *Nature communications* **10**, 4558, doi:10.1038/s41467-019-12576-w (2019).

566 42 Trubetskoy, V., Pardiñas, A. F., Qi, T., Panagiotaropoulou, G., Awasthi, S.,

567  Bigdeli, T. B. *et al.* Mapping genomic loci implicates genes and synaptic

568  biology in schizophrenia. *Nature* **604**, 502-508, doi:10.1038/s41586-022-

569  04434-5 (2022).

570 43 Watson, H. J., Yilmaz, Z., Thornton, L. M., Hübel, C., Coleman, J. R. I.,

571  Gaspar, H. A. *et al.* Genome-wide association study identifies eight risk loci

572  and implicates metabo-psychiatric origins for anorexia nervosa. *Nature*

573  *genetics* **51**, 1207-1214, doi:10.1038/s41588-019-0439-2 (2019).

574 44 Demontis, D., Walters, G. B., Athanasiadis, G., Walters, R., Therrien, K.,

575  Nielsen, T. T. *et al.* Genome-wide analyses of ADHD identify 27 risk loci,

576  refine the genetic architecture and implicate several cognitive domains. *Nature*

577  *genetics* **55**, 198-208, doi:10.1038/s41588-022-01285-8 (2023).

578 45 Martin, J., Walters, R. K., Demontis, D., Mattheisen, M., Lee, S. H., Robinson,

579  E. *et al.* A Genetic Investigation of Sex Bias in the Prevalence of Attention-

580  Deficit/Hyperactivity Disorder. *Biological psychiatry* **83**, 1044-1053,

581  doi:10.1016/j.biopsych.2017.11.026 (2018).

582 46 Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H. *et al.*

583  Identification of common genetic risk variants for autism spectrum disorder.

584  *Nature genetics* **51**, 431-444, doi:10.1038/s41588-019-0344-8 (2019).

585 47 Yu, D., Sul, J. H., Tsetsos, F., Nawaz, M. S., Huang, A. Y., Zelaya, I. *et al.*

Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic

Disorders Through Genome-Wide Association Studies. *The American journal*

of psychiatry **176**, 217-227, doi:10.1176/appi.ajp.2018.18070857 (2019).

48 Hatoum, A. S., Colbert, S. M. C., Johnson, E. C., Huggett, S. B., Deak, J. D.,

Pathak, G. *et al.* Multivariate genome-wide association meta-analysis of over

1 million subjects identifies loci underlying multiple substance use disorders.

Nature. Mental health **1**, 210-223, doi:10.1038/s44220-023-00034-y (2023).

49 Johnson, E. C., Demontis, D., Thorgeirsson, T. E., Walters, R. K., Polimanti,

R., Hatoum, A. S. *et al.* A large-scale genome-wide association study meta-

analysis of cannabis use disorder. *The lancet. Psychiatry* **7**, 1032-1045,

doi:10.1016/s2215-0366(20)30339-4 (2020).

50 Walters, R. K., Polimanti, R., Johnson, E. C., McClintick, J. N., Adams, M. J.,

Adkins, A. E. *et al.* Transancestral GWAS of alcohol dependence reveals

common genetic underpinnings with psychiatric disorders. *Nature*

neuroscience **21**, 1656-1669, doi:10.1038/s41593-018-0275-1 (2018).

51 Sanchez-Roige, S., Palmer, A. A., Fontanillas, P., Elson, S. L., Adams, M. J.,

Howard, D. M. *et al.* Genome-Wide Association Study Meta-Analysis of the

Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based

Cohorts. *The American journal of psychiatry* **176**, 107-118,

doi:10.1176/appi.ajp.2018.18040369 (2019).

52 Lloyd-Jones, L. R., Robinson, M. R., Yang, J. & Visscher, P. M.

Transformation of Summary Statistics from Linear Mixed Model Association

on All-or-None Traits to Odds Ratio. *Genetics* **208**, 1397-1408,

doi:10.1534/genetics.117.300360 (2018).

53   Bowden, J., Del Greco, M. F., Minelli, C., Davey Smith, G., Sheehan, N. A. &

Thompson, J. R. Assessing the suitability of summary data for two-sample

Mendelian randomization analyses using MR-Egger regression: the role of the

I2 statistic. *International journal of epidemiology* **45**, 1961-1974,

doi:10.1093/ije/dyw220 (2016).

54   Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization

analysis with multiple genetic variants using summarized data. *Genetic*

epidemiology **37**, 658-665, doi:10.1002/gepi.21758 (2013).

55   Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent

Estimation in Mendelian Randomization with Some Invalid Instruments Using

a Weighted Median Estimator. *Genetic epidemiology* **40**, 304-314,

doi:10.1002/gepi.21965 (2016).

56   Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with

invalid instruments: effect estimation and bias detection through Egger

regression. *International journal of epidemiology* **44**, 512-525,

doi:10.1093/ije/dyv080 (2015).

57   Altman, D. G. & Bland, J. M. Interaction revisited: the difference between two

estimates. *BMJ (Clinical research ed.)* **326**, 219,

doi:10.1136/bmj.326.7382.219 (2003).

58   Zuber, V., Grinberg, N. F., Gill, D., Manipur, I., Slob, E. A. W., Patel, A. *et al.*

Combining evidence from Mendelian randomization and colocalization:

Review and comparison of approaches. *American journal of human genetics*

109, 767-782, doi:10.1016/j.ajhg.2022.04.001 (2022).

59   Mansur, R. B., Ahmed, J., Cha, D. S., Woldeyohannes, H. O.,

Subramaniapillai, M., Lovshin, J. *et al.* Liraglutide promotes improvements in

objective measures of cognitive dysfunction in individuals with mood

disorders: A pilot, open-label study. *Journal of affective disorders* **207**, 114-

120, doi:10.1016/j.jad.2016.09.056 (2017).

60   Mansur, R. B., Zugman, A., Ahmed, J., Cha, D. S., Subramaniapillai, M., Lee,

Y. *et al.* Treatment with a GLP-1R agonist over four weeks promotes weight

loss-moderated changes in frontal-striatal brain structures in individuals with

mood disorders. *European neuropsychopharmacology : the journal of the*

European College of Neuropsychopharmacology **27**, 1153-1162,

doi:10.1016/j.euroneuro.2017.08.433 (2017).

61   Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting

cardiometabolic actions of GIP and GLP1. *Nature reviews. Endocrinology* **19**,

201-216, doi:10.1038/s41574-022-00783-3 (2023).

62   Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto,

J. L. *et al.* Trial of Lixisenatide in Early Parkinson's Disease. *The New*

England journal of medicine **390**, 1176-1185, doi:10.1056/NEJMoa2312323

(2024).

63　　McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A. *et*

al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's

disease: a randomised, double-blind, placebo-controlled trial. *The Lancet.*

Neurology **23**, 37-45, doi:10.1016/s1474-4422(23)00378-2 (2024).

64　　Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G.

M., Jr. *et al.* HPA axis in major depression: cortisol, clinical symptomatology

and genetic variation predict cognition. *Molecular psychiatry* **22**, 527-536,

doi:10.1038/mp.2016.120 (2017).

65　　Belvederi Murri, M., Prestia, D., Mondelli, V., Pariante, C., Patti, S., Olivieri,

B. *et al.* The HPA axis in bipolar disorder: Systematic review and meta-

analysis. *Psychoneuroendocrinology* **63**, 327-342,

doi:10.1016/j.psyneuen.2015.10.014 (2016).

66　　Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez,

L. E., Lakshmanan, M. *et al.* Effect of dulaglutide on cognitive impairment in

type 2 diabetes: an exploratory analysis of the REWIND trial. *The Lancet.*

Neurology **19**, 582-590, doi:10.1016/s1474-4422(20)30173-3 (2020).

67　　Zhou, L., Qu, H., Yang, L. & Shou, L. Effects of GLP1RAs on pregnancy rate

and menstrual cyclicity in women with polycystic ovary syndrome: a meta-

analysis and systematic review. *BMC endocrine disorders* **23**, 245,

doi:10.1186/s12902-023-01500-5 (2023).

68   Martel, M. M. Sexual selection and sex differences in the prevalence of

childhood externalizing and adolescent internalizing disorders. *Psychological*

bulletin **139**, 1221-1259, doi:10.1037/a0032247 (2013).

69   Yugar, L. B. T., Sedenho-Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A.

M., Sposito, A. C. & Cercato, C. The efficacy and safety of GLP-1 receptor

agonists in youth with type 2 diabetes: a meta-analysis. *Diabetology &*

metabolic syndrome **16**, 92, doi:10.1186/s13098-024-01337-5 (2024).

70   MacDonald, P. E., El-Kholy, W., Riedel, M. J., Salapatek, A. M., Light, P. E. &

Wheeler, M. B. The multiple actions of GLP-1 on the process of glucose-

stimulated insulin secretion. *Diabetes* **51 Suppl 3**, S434-442,

doi:10.2337/diabetes.51.2007.s434 (2002).

71   Adams, D. M., Reay, W. R., Geaghan, M. P. & Cairns, M. J. Investigation of

glycaemic traits in psychiatric disorders using Mendelian randomisation

revealed a causal relationship with anorexia nervosa.

Neuropsychopharmacology : official publication of the American College of

Neuropsychopharmacology **46**, 1093-1102, doi:10.1038/s41386-020-00847-w

(2021).

72   Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L. *et al.*

Benefits and harms of drug treatment for type 2 diabetes: systematic review

and network meta-analysis of randomised controlled trials. *BMJ (Clinical*

research ed.) **381**, e074068, doi:10.1136/bmj-2022-074068 (2023).

73 Ye, C. J., Liu, D., Chen, M. L., Kong, L. J., Dou, C., Wang, Y. Y. *et al.*

Mendelian randomization evidence for the causal effect of mental well-being

on healthy aging. *Nature human behaviour*, doi:10.1038/s41562-024-01905-9

(2024).

74 Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J. & Zhang, J.

H. Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate

inflammation after intracerebral hemorrhage. *Journal of cerebral blood flow*

and metabolism : official journal of the International Society of Cerebral

Blood Flow and Metabolism **32**, 2201-2210, doi:10.1038/jcbfm.2012.133

(2012).

75 Steinberg, G. R. & Carling, D. AMP-activated protein kinase: the current

landscape for drug development. *Nature reviews. Drug discovery* **18**, 527-551,

doi:10.1038/s41573-019-0019-2 (2019).

(a) BMI lowering

■ Lower BMI by GLP-1R activation　⊖ Lower BMI

(b) HbA1c lowering

■ Lower HbA1c by GLP-1R activation　⊖ Lower HbA1c

Outcome	Sample size	(a) Beta (95% CI)	(a) P value	(b) Beta (95% CI)	(b) P value
Well-being spectrum	2,370,390	0.06 (0.03 to 0.08)	<.001	0.003 (-0.02 to 0.02)	.81
		0.003 (0.00 to 0.01)	.04	-0.001 (-0.00 to 0.00)	.35
Life satisfaction	80,852	0.08 (0.04 to 0.12)	<.001	0.002 (-0.03 to 0.03)	.90
		0.003 (-0.00 to 0.01)	.05	-0.001 (-0.00 to 0.00)	.42
Positive affect	410,603	0.07 (0.04 to 0.10)	<.001	0.002 (-0.02 to 0.03)	.88
		0.002 (-0.00 to 0.01)	.16	-0.001 (-0.00 to 0.00)	.38
Neuroticism	582,989	-0.09 (-0.13 to -0.05)	<.001	-0.003 (-0.04 to 0.03)	.88
		-0.004 (-0.01 to 0.00)	.05	0.001 (-0.00 to 0.00)	.54
Depressive symptoms	1,295,946	-0.06 (-0.09 to -0.03)	<.001	-0.001 (-0.02 to 0.02)	.90
		-0.004 (-0.01 to -0.00)	.002	0.000 (-0.00 to 0.00)	.63

(a) axis: -0.15　-0.05　0.05　0.15

(b) axis: -0.05　0　0.05

Figure 1. IVW MR estimates for the associations of GLP-1R activation with mental health well-being.

BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR,

Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on

GLP1R variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive

associations with the well-being spectrum, life satisfaction, and positive affect and negative associations with neuroticism and depressive

symptoms indicate better mental health well-being. Estimates are presented in standard deviation units for mental health well-being per 1-kg/m^2

decrease in BMI or per 1-mmol/mol decrease in HbA1c.

(a) BMI lowering

■ Lower BMI by GLP-1R activation   ⊖ Lower BMI

Outcome	Case/control	Odds ratio (95% CI)	P value
Depression	170,756/329,443	0.83 (0.74 to 0.94)	.003
		0.98 (0.97 to 0.99)	<.001
Post-partum depression	17,339/53,426	0.62 (0.43 to 0.89)	.01
		0.98 (0.96 to 1.00)	.03
Bipolar disorder	41,917/371,549	0.61 (0.47 to 0.79)	<.001
		1.00 (0.98 to 1.02)	.77
Bipolar disorder I	25,060/449,978	0.58 (0.42 to 0.80)	<.001
		1.01 (0.98 to 1.03)	.57
Bipolar disorder II	6,781/364,075	0.56 (0.32 to 0.97)	.04
		1.00 (0.97 to 1.03)	.94
PTSD	23,212/151,447	0.71 (0.47 to 1.07)	.10
		0.94 (0.92 to 0.96)	<.001
Schizophrenia	53,386/77,258	0.88 (0.69 to 1.11)	.28
		1.03 (1.01 to 1.05)	.01
Anorexia nervosa	16,992/55,525	0.95 (0.65 to 1.39)	.79
		1.10 (1.07 to 1.12)	<.001
ADHD	38,691/186,843	0.72 (0.55 to 0.94)	.01
		0.89 (0.87 to 0.90)	<.001
Autism spectrum disorder	18,381/27,969	0.69 (0.47 to 1.02)	.06
		0.98 (0.95 to 1.00)	.05
Tourette syndrome	4,819/9,488	1.27 (0.62 to 2.59)	.52
		0.97 (0.93 to 1.01)	.14

X-axis: 0.4 0.6 1.0 1.6 2.7

(b) HbA1c lowering

■ Lower HbA1c by GLP-1R activation   ⊖ Lower HbA1c

Odds ratio (95% CI)	P value
1.03 (0.94 to 1.13)	.54
1.00 (1.00 to 1.00)	.90
0.83 (0.61 to 1.14)	.25
1.00 (0.99 to 1.01)	.41
1.19 (0.97 to 1.46)	.09
1.01 (0.99 to 1.02)	.34
1.18 (0.92 to 1.53)	.20
1.01 (1.00 to 1.02)	.25
1.47 (0.93 to 2.33)	.10
1.00 (0.99 to 1.02)	.86
1.24 (0.88 to 1.74)	.22
1.00 (0.99 to 1.01)	.64
1.13 (0.93 to 1.37)	.21
1.00 (0.99 to 1.01)	.45
1.53 (1.13 to 2.09)	.007
1.02 (1.00 to 1.03)	.02
0.89 (0.73 to 1.09)	.27
0.99 (0.98 to 1.00)	.02
0.75 (0.55 to 1.03)	.07
1.00 (0.99 to 1.02)	.43
0.54 (0.31 to 0.94)	.03
0.99 (0.97 to 1.01)	.18

X-axis: 0.4 0.6 1.0 1.6 2.7

Figure 2. IVW MR estimates for the associations of GLP-1R activation with the risk of mental health disorders.

ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization; PTSD, post-traumatic stress disorder. Black squares denote

genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically

predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Estimates are presented as odds ratio per 1-kg/m^2 decrease in BMI

or per 1-mmol/mol decrease in HbA1c.

Figure 3. IVW MR estimates for the associations of GLP-1R activation with the risk of substance use disorders and AUDIT scores.

AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b)

lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c

based on genome-wide variants. Positive associations with AUDIT scores indicate higher risk of alcohol use disorders. Estimates are presented

in standard deviation unit for substance use disorder risk, as logodds for cannabis use disorder and alcohol dependence, and as log10 transformed

score for AUDIT scores per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.

Figure 4. Colocalization analyses for BMI and each significant outcome at the *GLP1R* gene.

BMI, body mass index. Probability for colocalization means the posterior probability of a shared variant associated with both traits; conditional

probability means the posterior probability of a shared variant associated with both traits conditional on the presence of a variant associated with

the outcome. Conditioning on the presence of a shared variant associated with both traits, the variant highlighted with a label had the largest

probability of being the shared variant.